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Cervical cancer screening strategies using visual inspection or cytology may have subopti-
mal diagnostic accuracy for detection of precancer in women living with HIV (WLHIV). The
optimal screen and screen–triage strategy, age to initiate, and frequency of screening for
WLHIV remain unclear. This study evaluated the sensitivity, specificity, and positive predic-
tive value of different cervical cancer strategies in WLHIV in Africa.
Methods and findings
WLHIV aged 25–50 years attending HIV treatment centres in Burkina Faso (BF) and South
Africa (SA) from 5 December 2011 to 30 October 2012 were enrolled in a prospective evalu-
ation study of visual inspection using acetic acid (VIA) or visual inspection using Lugol’s
iodine (VILI), high-risk human papillomavirus DNA test (Hybrid Capture 2 [HC2] or car-
eHPV), and cytology for histology-verified high-grade cervical intraepithelial neoplasia
(CIN2+/CIN3+) at baseline and endline, a median 16 months later. Among 1,238 women
(BF: 615; SA: 623), median age was 36 and 34 years (p < 0.001), 28.6% and 49.6% ever
had prior cervical cancer screening (p < 0.001), and 69.9% and 64.2% were taking ART at
enrolment (p = 0.045) in BF and SA, respectively. CIN2+ prevalence was 5.8% and 22.4%
in BF and SA (p < 0.001), respectively. VIA had low sensitivity for CIN2+ (44.7%, 95% confi-
dence interval [CI] 36.9%–52.7%) and CIN3+ (56.1%, 95% CI 43.3%–68.3%) in both
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countries, with specificity for�CIN1 of 78.7% (95% CI 76.0%–81.3%). HC2 had sensitivity
of 88.8% (95% CI 82.9%–93.2%) for CIN2+ and 86.4% (95% CI 75.7%–93.6%) for CIN3+.
Specificity for�CIN1 was 55.4% (95% CI 52.2%–58.6%), and screen positivity was 51.3%.
Specificity was higher with a restricted genotype (HPV16/18/31/33/35/45/52/58) approach
(73.5%, 95% CI 70.6%–76.2%), with lower screen positivity (33.7%), although there was
lower sensitivity for CIN3+ (77.3%, 95% CI 65.3%–86.7%). In BF, HC2 was more sensitive
for CIN2+/CIN3+ compared to VIA/VILI (relative sensitivity for CIN2+ = 1.72, 95% CI 1.28–
2.32; CIN3+: 1.18, 95% CI 0.94–1.49). Triage of HC2-positive women with VIA/VILI reduced
the number of colposcopy referrals, but with loss in sensitivity for CIN2+ (58.1%) but not for
CIN3+ (84.6%). In SA, cytology high-grade squamous intraepithelial lesion or greater (HSIL
+) had best combination of sensitivity (CIN2+: 70.1%, 95% CI 61.3%–77.9%; CIN3+:
80.8%, 95% CI 67.5%–90.4%) and specificity (81.6%, 95% CI 77.6%–85.1%). HC2 had
similar sensitivity for CIN3+ (83.0%, 95% CI 70.2%–91.9%) but lower specificity compared
to HSIL+ (42.7%, 95% CI 38.4%–47.1%; relative specificity = 0.57, 95% CI 0.52–0.63),
resulting in almost twice as many referrals. Compared to HC2, triage of HC2-positive
women with HSIL+ resulted in a 40% reduction in colposcopy referrals but was associated
with some loss in sensitivity. CIN2+ incidence over a median 16 months was highest among
VIA baseline screen-negative women (2.2%, 95% CI 1.3%–3.7%) and women who were
baseline double-negative with HC2 and VIA (2.1%, 95% CI 1.3%–3.5%) and lowest among
HC2 baseline screen-negative women (0.5%, 95% CI 0.1%–1.8%). Limitations of our study
are that WLHIV included in the study may not reflect a contemporary cohort of WLHIV initiat-
ing ART in the universal ART era and that we did not evaluate HPV tests available in study
settings today.
Conclusions
In this cohort study among WLHIV in Africa, a human papillomavirus (HPV) test targeting 14
high-risk (HR) types had higher sensitivity to detect CIN2+ compared to visual inspection
but had low specificity, although a restricted genotype approach targeting 8 HR types
decreased the number of unnecessary colposcopy referrals. Cytology HSIL+ had optimal
performance for CIN2+/CIN3+ detection in SA. Triage of HPV-positive women with HSIL+
maintained high specificity but with some loss in sensitivity compared to HC2 alone.
Author summary
Why was this study done?
• Invasive cervical cancer is the second most common cancer among women in low- and
middle-income countries and a leading cause of cancer-related death in women in sub-
Saharan Africa.
• Women living with human immunodeficiency virus (WLHIV) have an increased risk of
cervical cancer and precancer. The majority of WLHIV live in low- and middle-income
countries, where access to cervical cancer screening and treatment of precancerous cer-
vical lesions is limited.
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• Screening approaches most commonly used in sub-Saharan Africa, including visual
inspection of the cervix and cervical cytology, which checks for cervical cell abnormali-
ties, have shown variable diagnostic accuracy to detect precancerous lesions. Molecular-
based screening approaches, such as human papillomavirus (HPV) DNA testing, which
screens for oncogenic HPV infection, have shown high sensitivity for cervical precancer
but can result in over-referral to colposcopy, a procedure to determine eligibility for
treatment.
• The optimal screening test, age to begin screening, and frequency of screening for
WLHIV remain uncertain.
What did the researchers do and find?
• We evaluated several cervical cancer screening strategies in over 1,200 WLHIV in sub-
Saharan Africa.
• We found that an HPV DNA test identified a greater number of women with precancer
compared to visual inspection and cytology methods. However, there was a greater pro-
portion of women without precancer who had a positive HPV DNA test, meaning a tri-
age test using cytology or visual inspection was required to determine treatment
eligibility.
• Simple user-applied modifications to the HPV-DNA-based test resulted in fewer
women without precancer testing positive and fewer women needing triage.
• In settings with adequate infrastructure, cervical cytology was a useful triage test for
HPV-positive women.
What do these findings mean?
• Our data contribute to the evidence on choice of screening strategies for detection of
cervical precancer among WLHIV in low- and middle-income settings.
• HPV DNA tests can play an important role in cervical cancer screening, especially in
the era of universal antiretroviral therapy and where availability of self-sampling will
facilitate screening participation.
• Prevention of cervical cancer should rank high as a public health priority in sub-Saharan
Africa since WLHIV represent a group at very high risk of cervical precancer.
Introduction
In May 2018, the Director-General of the World Health Organization (WHO) announced a
global call for action towards the elimination of invasive cervical cancer (ICC) as a public
health problem, calling for more innovative technologies for detection of high-grade cervical
intraepithelial neoplasia (CIN) grade 2 and higher (CIN2+) and better strategies to increase
screening coverage and uptake [1]. The 2030 cervical cancer elimination targets include vacci-
nating 90% of eligible girls against human papillomavirus (HPV), screening 70% of eligible
women for cervical cancer, and effectively treating 90% of those with a positive lesion [2].
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Since the introduction of HPV vaccination, cervical cancer screening in high-income settings
has shifted from the identification of cellular changes in cytology towards the molecular detection
of high-risk HPV (HR-HPV) types as the form of primary screening, allowing for increased auto-
mation and standardisation of diagnostic procedures. Studies among regularly screened women
in Europe have shown that HPV-based screening reduces the risk of ICC by up to 70% compared
to cervical cytology, also allowing extension of screening intervals due to the higher negative pre-
dictive value (NPV) [3]. Approaches using HPV DNA tests can be easily adapted to resource-lim-
ited settings, allow for self-collected samples, and are less observer dependent than visual
inspection methods, which have variable sensitivity and specificity among women living with
HIV (WLHIV) [4–6]. However, HPV DNA tests can detect many transient infections, meaning
that their specificity for high-grade CIN is low, especially in populations with high prevalence of
HR-HPV [7]. This is problematic among WLHIV, who are more likely to have multiple HR-HPV
co-infections with a broader range of HR-HPV genotypes [8] and have a higher risk of HR-HPV
incidence and persistence compared to HIV-negative women [9]. However, there is increasing
evidence that WLHIV on effective ART with sustained HIV viral suppression have lower preva-
lence of HR-HPV [10], which may impact on diagnostic accuracy of HPV-DNA-based testing in
screening and screening–triage for CIN2+ detection. Current WHO guidelines recommend that
cervical cancer screening should be started in sexually active girls and women, as soon as they
have tested positive for HIV, and if the screening test is negative, a repeat test should be done
within 3 years [11], although more recent evidence from cross-sectional and prospective studies is
being considered in the revision of these recommendations, including optimal screen and screen–
triage modalities, age to initiate screening, and screening intervals.
The majority of WLHIV live in low- and middle-income countries (LMICs), where cervical
cancer incidence is high [12] but where cervical cancer screening coverage and linkage to care
is low [13,14] and largely unknown for WLHIV [15], as infrastructure and personnel require-
ments for screening and management put high demands on the health systems. Furthermore,
cervical cancer screening approaches more commonly utilised in LMICs, including visual
inspection methods and cervical cytology, have variable and often suboptimal sensitivity and
specificity for CIN2+ detection and can lack reproducibility both in women in the general
population and among WLHIV. Screening and screening–triage strategies that can be feasibly
implemented and that have high diagnostic accuracy to detect CIN2+/CIN3+ are needed. We
previously evaluated the association of HIV-related factors with the natural history of HPV
infection and CIN2+/CIN3+ in a prospective cohort of WLHIV followed over a median 16
months in Burkina Faso (BF) and South Africa (SA) [16,17]. The primary objective of the cur-
rent study was to evaluate the diagnostic accuracy of 3 screening approaches (index tests):
HR-HPV DNA tests (Hybrid Capture 2 [HC2] and careHPV), visual inspection (standard of
care in BF), and cervical cytology (standard of care in SA) for the detection of prevalent histol-
ogy-confirmed CIN2+/CIN3+ (reference method) in screening and in triage (Analysis 1). Sec-
ondary objectives were to evaluate the diagnostic accuracy of those test strategies by ART
status and age (Analysis 2). To inform on frequency of screening, we evaluated CIN2+ inci-
dence over a median 16 months among baseline screen-negative WLHIV (Analysis 3).
Methods
Study design and participants
We enrolled WLHIV recruited from the Hôpital de Jour (the HIV outpatient clinic of the
Internal Medicine Department at Centre Hospitalier Universitaire Yalgado [CHU-Yalgado]),
Ouagadougou, BF, and the Esselen Street Clinic (a primary health clinic) and Ward 21 of Hill-
brow Community Health Centre (an ART initiation site) in Johannesburg, SA, from 5
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December 2011 to 30 October 2012 in a prospective evaluation study of cervical cancer screen-
ing strategies, as previously described [17]. In brief, women were enrolled consecutively in the
HARP (HPV in Africa Research Partnership) study if they were HIV-1 seropositive, aged 25–
50 years, and resident in the study city. Women were excluded if they had a history of prior
treatment for cervical cancer, had previous hysterectomy, or were pregnant or less than 8
weeks postpartum. Enrolment was stratified in a 2:1 ratio of ART users:ART-naïve WLHIV.
Participants were followed up every 6 months for CD4+ T lymphocyte cell count monitoring
and up to month 18, when procedures similar to baseline were repeated (median 16 months
after baseline). All women provided written informed consent. Ethical approval was granted
by the Ministry of Health in BF (no. 2012-12-089), the University of the Witwatersrand in SA
(no. 110707), and the London School of Hygiene & Tropical Medicine (no. 7400).
Procedures
At baseline and endline (median 16 months later) visits, cervical samples were collected from
all women using a Digene cervical sampler (Qiagen, Courtaboeuf, France) for HPV DNA test-
ing and genotyping, a cytobrush for Papanicolaou smear cytology, and swabs from the ecto/
endocervix and vagina to detect sexually transmitted infections (STIs). All participants had a
visual inspection using acetic acid (VIA) and a visual inspection using Lugol’s iodine (VILI)
performed by trained nurses following the International Agency for Research on Cancer
(IARC) guidelines [18]. All participants were referred for colposcopy at a median of 12 weeks
(interquartile range [IQR] 8–15) following the baseline visit, performed by trained colposco-
pists applying the Swede score for clinical severity grading [19]. Colposcopists were aware of
VIA/VILI, cytology, and HPV DNA test results. Systematic 4-quadrant cervical biopsy, includ-
ing directed biopsy of any suspicious lesions, was performed for participants who had abnor-
malities detected by cytology (atypical squamous cells of undetermined significance, or greater
[ASCUS+]) or VIA/VILI or during colposcopy, or who were HR-HPV DNA positive. A
venous blood sample was collected to confirm HIV-1 serostatus if needed, and to obtain HIV-
1 RNA plasma viral load and CD4+ T cell count.
HR-HPV testing using the qualitative Digene HC2, which detects 13 HR-HPV types
(HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68), at baseline was performed
centrally at the University of Montpellier (UM) virology laboratory by trained laboratory tech-
nicians in France as previously described [20]. The qualitative careHPV (Qiagen, Gaithers-
burg, MD), which detects 14 HR-HPV types (HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56,
-58, -59, -66, and -68), was performed at endline by trained laboratory technicians at the Cen-
tre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, BF, and the
National Health Laboratory Service (NHLS), Johannesburg, SA. A high level of agreement
between HC2 and careHPV was reported in a nested study [21]. Quality assurance was per-
formed by the UM virology laboratory. Results were displayed by the careHPV test controller
without additional specification of the luminescent signal intensity. Genotyping with the
INNO-LiPA HPV Genotyping Extra assay (Innogenetics, Courtaboeuf, France) was conducted
at UM as previously described [20]. Conventional cytological reading was based on the Papa-
nicolaou method and performed at the pathology department at CHU-Yalgado in Ouagadou-
gou and the NHLS in Johannesburg according to the Bethesda classification system [22], with
a quality assurance scheme organised by the UM virology laboratory for both countries. The
NHLS lab was also subscribed to the Cytopathology Quality Assurance Program of the Royal
College of Pathologists of Australasia Quality Assurance Program.
Cervical biopsies were processed at the local pathology laboratories and read using the
3-tier CIN classification system [23]. The reference standard of histology was classified as
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‘negative’ (�CIN1) or ‘positive’ (CIN2+) based on the highest reading across all findings from
the 4-quadrant biopsies and endocervical curettage if collected. The histopathologist was blind
to VIA/VILI, cytology, and HPV DNA test results but was aware of colposcopy diagnosis. All
histological slides from women with a local diagnosis of CIN2+ and approximately 10% of
slides from women with�CIN1 histological findings were reviewed by the HARP Endpoint
Committee of 5 pathologists, for consensus classification, which showed high agreement [24].
Participants were recalled for CIN2+ management according to local guidelines at each
site, if found to have CIN2+ lesions by histology at the baseline and/or endline visit. The man-
agement visit was scheduled at the earliest convenient date once the result was known. Due to
demands on local health services in SA, this often meant that CIN2+ management was sched-
uled up to 14 months after diagnosis. CIN2+ status was therefore defined according to whether
the participant had received CIN2+ management between enrolment and follow-up. CIN2
+ prevalence at baseline was defined as the number of women with CIN2+ detected at baseline
among all women enrolled in the HARP study. Cumulative CIN2+ prevalence at endline was
defined as the number of women with CIN2+ detected at endline among all women attending
the endline visit, irrespective of whether women were treated for prevalent CIN2+ between
baseline and endline. CIN2+ incidence was defined as newly detected CIN2+ at the endline
visit among women without CIN2+ at baseline.
Statistical analysis
In the analysis of diagnostic accuracy (Analysis 1), the index tests evaluated included VIA alone,
VIA/VILI (co-testing when either test is positive among all women screened), cytology (using
thresholds of low-grade squamous intraepithelial lesion or greater [LSIL+] and high-grade squa-
mous intraepithelial lesion or greater [HSIL+]), and HR-HPV DNA (Digene HC2) for the detection
of histology-confirmed CIN2+ and CIN3+ (reference method) at baseline. Sensitivity, specificity,
positive predictive value (PPV) complement of NPV (1 − NPV), the number of referrals to colpos-
copy that would be generated for each CIN2+ or CIN3+ case identified (number needed to refer
[NNR] = 1/PPV) [25], and the number of referrals per 1,000 women screened were reported for
each of the index tests. For HC2, we considered test positivity at varying thresholds of the relative
light unit (RLU) between�1 and�20, corresponding with increasing HPV viral load [26], to eval-
uate the threshold effect on test specificity to distinguish CIN2+/CIN3+. Among HR-HPV (HC2)
positive women, we evaluated the diagnostic accuracy of triage approaches, including VIA, VIA/
VILI, cytology (ASCUS+ and HSIL+), a combination of HPV16/18 genotyping and cytology (test
positive if HPV16 or HPV18 positive, or cytology [ASCUS+ or HSIL+] when negative for both
HPV16 and HPV18), and combination of HPV16/18 genotyping and VIA (test positive if HPV16
or HPV18 positive, or VIA abnormal when negative for both HPV16 and HPV18).
We evaluated the diagnostic accuracy of a restricted genotyping approach using results of
the INNO-LiPA genotyping assay in the following combinations (positive for any genotype):
HPV16; HPV16/18/45 (3 high-risk [HR] types), and HPV16/18/45/31/33/35/52/58 (8 HR
types). Because of the low limit of detection of INNO-LiPA and to improve clinical relevancy,
test positivity was defined as positivity for any of those genotypes among women who were
also HC2 positive. We also evaluated the diagnostic accuracy of an HPV-based test targeting
HR types previously reported to be most significantly associated with CIN3+ in the HARP
cohort [27]. Relative sensitivity (RSen) and relative specificity (RSpec) and 95% confidence
intervals (CIs) of screening tests compared to the standard of care in each country (VIA/VILI
in BF and HSIL+ cytology in SA) were calculated [28].
In order to observe the performance of screening strategies in an already screened popula-
tion, we evaluated the diagnostic accuracy of endline VIA/VILI, HPV DNA (careHPV), and
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cytology for cumulative CIN2+ detection at endline, excluding women who were treated for
prevalent CIN2+ at baseline.
To evaluate the association of HIV-related factors with diagnostic accuracy of screening
strategies, diagnostic accuracy for CIN2+/CIN3+ was evaluated separately among women on
prolonged ART (>2 years), women on short-duration ART (�2 years), and ART-naïve women
at baseline (Analysis 2). Diagnostic accuracy was also evaluated according to age at screening
(Analysis 2). The cumulative incidence of CIN2+ at endline was calculated among women who
screened negative for each of the screening strategies at baseline (Analysis 3). Analyses for diag-
nostic accuracy were conducted for discrete outcomes of CIN2+ and CIN3+. Data are presented
separately for each country. Data were analysed using Stata (version 16) and according to the
study statistical analysis plan (S1 Text). This article was reported according to the Standards for
Reporting of Diagnostic Accuracy (STARD) statement (S1 Checklist) [29]. The dataset is avail-
able in the Mendeley Data online repository at doi: 10.17632/yd5ygw38vj.1.
Results
Study population
Of 1,395 women screened, 1,238 (89%) were enrolled in the HARP study (BF: 615; SA: 623;
Fig 1). Overall, 1,130 (91.3%) participants (BF: 90.1%; SA: 92.5%) had valid histology and were
included in the final analysis. The median time from enrolment, when index tests were con-
ducted, to the colposcopy visit, when biopsy was taken, if indicated, for histology verification,
was 2.9 months (IQR 2.1–3.8). CIN2+ prevalence was 5.8% (32/554) in BF and 22.4% (129/
576) in SA (p< 0.001; Table 1). CIN3+ prevalence was 2.3% (13/554) in BF and 9.2% (53/576)
in SA (p< 0.001).
The median age of participants was 36 (IQR 32–42) years in BF and 34 (IQR 30–39) years
in SA (Table 1). About half (49.0%) of SA participants had ever had a Pap smear, and a fifth
(21.5%) of BF participants had ever had a VIA/VILI examination, the respective primary cervi-
cal cancer screening modality in each country. At enrolment, 387 (69.9%) participants were on
ART in BF and 370 (64.2%) in SA (p = 0.045), reflecting the 2:1 stratification ratio. Just over a
third of women were taking ART for>2 years. The median CD4+ T cell count among women
on ART for a prolonged duration (>2 years), women on ART for a short duration ART (�2
years), and ART-naïve women was 478 (IQR 366–478), 394 (IQR 276–573), and 392 (IQR
310–591) cells/μl, respectively, in BF and 476 (IQR 372–626), 326 (IQR 207–453), and 440
(IQR 347–595) cells/μl, respectively, in SA. The corresponding values for HIV-1 plasma viral
load were 40 (IQR 40–40), 40 (IQR 40–101), and 23,171 (IQR 1,943–166,067) copies/ml,
respectively, in BF and 109 (IQR 40–560), 141 (IQR 40–743), and 19,650 (IQR 4,800–57,500)
copies/ml, respectively, in SA.
The prevalence of HR-HPV by INNO-LiPA genotyping was 57.7% (315/556) in BF and
79.3% (456/575) in SA (p< 0.001). The prevalence of HR-HPV by HC2 was 41.8% (229/554)
in BF and 59.7% (342/576) in SA (Table 1).
Diagnostic accuracy of screening strategies for CIN2+ and CIN3+ detection
at baseline
At baseline, positivity for each of the screening tests—VIA, VIA/VILI, ASCUS+, HSIL+, and
HR-HPV DNA (HC2)—was 21.0%, 23.9%, 25.8%, 4.5%, and 41.8%, respectively, in BF, and
28.1%, 41.5%, 93.4%, 30.1%, and 59.7%, respectively, in SA (Table 1).
VIA had low sensitivity for CIN2+/CIN3+ (countries combined—CIN2+: 44.7%, 95% CI
36.9%–52.7%; CIN3+: 56.1%, 95% CI 43.3%–68.3%), with specificity for�CIN1 of 78.7%
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(95% CI 76.0%–81.3%; Tables 2 and 3). The addition of VILI to VIA (either positive) resulted
in an increase in sensitivity (CIN2+: 61.5%, 95% CI 53.5%–69.0%; CIN3+: 69.7%, 57.1%–
80.4%), with highest sensitivity observed for CIN3+ in BF only (84.6%, 95% CI 54.6%–98.1%;
S1 Table; Fig 2). The number of referrals to colposcopy varied by country for VIA/VILI: 239
women per 1,000 women screened in BF and 415 in SA (S2 Table). The PPV varied by country,
reflecting the difference in CIN3+ prevalence: 8.3% (95% CI 4.2%–14.4%) and 14.6% (95% CI
10.4%–19.8%) in BF and SA, respectively.
Fig 1. Study flowchart. BF, Burkina Faso; HC-II, Hybrid Capture 2; HPV, human papillomavirus; SA, South Africa;
VIA, visual inspection using acetic acid; VILI, visual inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.g001
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Diagnostic accuracy of cervical cytology varied by country. In SA, cytology using a cutoff of
HSIL+ had the best combination of sensitivity (CIN2+: 70.1%, 95% CI 61.3%–77.9%; CIN3+:
80.8%, 95% CI 67.5%–90.4%) and specificity for�CIN1 (81.6%, 95% CI 77.6%–85.1%; Fig 3)
and would result in 301 referrals per 1,000 women, with a PPV for CIN3+ of 24.9% (95% CI
Table 1. Patient characteristics and screening test positivity at baseline and endline in Burkina Faso and South Africa.










Age, median (IQR) 36 (32, 42) — 34 (30, 39) — <0.001
Ever had prior cervical cancer screening 158 (28.6) — 285 (49.6) — <0.001
Ever had Pap smear 69 (12.5) — 282 (49.0) — <0.001
Ever had visual inspection exam 119 (21.5) — 15 (2.6) — <0.001
Taking hormonal contraception 290 (52.4) — 492 (85.4) — <0.001
Years since HIV diagnosis — —
<5 years 258 (46.6) — 325 (56.4) — 0.003
5–9 years 226 (40.8) — 186 (32.3) —
�10 years 70 (12.6) — 65 (11.3) —
ART status — —
ART >2 years 220 (39.7) — 207 (35.9) — 0.129
ART�2 years 167 (30.1) — 163 (28.3) —
ART naïve 167 (30.1) — 206 (35.8) —
HIV-1 PVL1 among ART-naïve women, median (IQR) 14,944 (40, 128,897) — 18,150 (3,800, 55,400) — <0.001
HIV-1 PVL suppression2 among ART users 336 (86.8) — 299 (80.8) —
Screen test positive
VIA only positive 116 (21.0) 62 (13.6) 162 (28.1) 95 (20.0)
VILI only positive 130 (23.5) 68 (15.1) 219 (38.0) 208 (43.7)
VIA or VILI positive (VIA/VILI) 132 (23.9) 76 (16.6) 239 (41.5) 220 (46.2)
Cytology ASCUS+ 137 (25.8) 45 (10.9) 524 (93.4) 459 (97.3)
Cytology LSIL+ 120 (22.6) 34 (8.2) 504 (89.8) 378 (80.1)
Cytology HSIL+ 24 (4.5) 7 (1.7) 169 (30.1) 85 (18.0)
HR-HPV DNA positive3 229 (41.8) 190 (41.9) 342 (59.7) 281 (59.3)
Histology-confirmed grade
<CIN1 373 (67.3) 383 (83.8) 262 (45.5) 397 (83.4)
CIN1 149 (26.9) 68 (14.9) 185 (32.1) 32 (6.7)
CIN2 19 (3.4) 5 (1.1) 76 (13.2) 34 (7.1)
CIN3 11 (2.0) 1 (0.2) 53 (9.2) 13 (2.7)
Invasive cervical cancer 2 (0.4) 0 (0.0) 0 (0.0) 0 (0.0)
�CIN1 522 (94.2) 451 (98.7) 447 (77.6) 429 (90.1)
CIN2+ 32 (5.8) 6 (1.3) 129 (22.4) 47 (9.9)
CIN3+ 13 (2.3) 1 (0.2) 53 (9.2) 13 (2.7)
Data are n (%) unless otherwise indicated.
1RNA, copies/ml.
2 PVL < 1,000 copies/ml.
3Using Hybrid Capture 2 at baseline (cutoff of 1 relative light unit) and careHPV at endline.
ASCUS+, atypical squamous cells of undetermined significance, or greater; CIN, cervical intraepithelial neoplasia; HR-HPV, high-risk human papillomavirus; HSIL,
high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; PVL, plasma viral load; VIA, visual inspection using acetic acid; VILI,
visual inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.t001
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1Positive for HC2 (using a threshold of �10 RLU) and any of HPV16/18/31/33/35/45/52/58.
2Calculated among women testing positive for HPV DNA, using HC2� 1 RLU to define test positive.
3Test positive if HPV16 or HPV18 positive, or cytology (HSIL+) when negative for both HPV16 and HPV18.
4Test positive if HPV16 or HPV18 positive, or VIA abnormal when negative for both HPV16 and HPV18.
ASCUS+, atypical squamous cells of undetermined significance, or greater; AUC, area under the curve; BF, Burkina Faso; CIN, cervical intraepithelial neoplasia; HC2,
Hybrid Capture 2; HPV, human papillomavirus; HR, high risk; HR-HPV, high-risk human papillomavirus; HSIL+, high-grade squamous intraepithelial lesion or
greater; NPV, negative predictive value; PPV, positive predictive value; RLU, relative light unit; SA, South Africa; VIA, visual inspection using acetic acid; VILI, visual
inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.t002
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Table 3. Performance of screening strategies for detection of prevalent CIN3+ among 1,130 women living with HIV (554 in BF; 576 in SA).
Strategy Tests
performed, n
Number of colposcopies needed to
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1Positive for HC2 (using a threshold of �10 RLU) and any of HPV16/18/31/33/35/45/52/58.
2Calculated among women testing positive for HPV DNA, using HC2� 1 RLU to define test positive.
3Test positive if HPV16 or HPV18 positive, or cytology (HSIL+) when negative for both HPV16 and HPV18.
4Test positive if HPV16 or HPV18 positive, or VIA abnormal when negative for both HPV16 and HPV18.
ASCUS+, atypical squamous cells of undetermined significance, or greater; AUC, area under the curve; BF, Burkina Faso; CIN, cervical intraepithelial neoplasia; HC2,
Hybrid Capture 2; HPV, human papillomavirus; HR, high risk; HR-HPV, high-risk human papillomavirus; HSIL+, high-grade squamous intraepithelial lesion or
greater; NPV, negative predictive value; PPV, positive predictive value; RLU, relative light unit; SA, South Africa; VIA, visual inspection using acetic acid; VILI, visual
inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.t003
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18.5%–32.1%; Table 3). In BF, a cutoff of ASCUS+ had an optimal combination of sensitivity
for CIN3+ of 72.7% (95% CI 39.0%–94.0%) and specificity for�CIN1 of 77.3% (95% CI
73.4%–80.9%).
HC2 using a threshold of�1 RLU had the highest sensitivity of all screening strategies for
CIN2+ (88.8%, 95% CI 82.9%–93.2%) and CIN3+ (86.4%, 95% CI 75.7%–93.6%) but the low-
est specificity (55.4%, 95% CI 52.2%–58.6%; Tables 2 and 3), and the proportion of women
testing positive was 51.3% (41.8% in BF and 59.7% in SA, p< 0.001). Increasing the threshold
to�20 RLU resulted in fewer women screening positive (35.5% overall, 29.2% in BF and
41.5% in SA) and increased the specificity to 71.4% (95% CI 68.4%–74.2%) but with loss in
sensitivity (CIN2+: 76.4%, 95% CI 69.1%–82.7%; CIN3+: 75.8%, 95% CI 63.6%–85.5%). In BF,
the number of colposcopy referrals was similar to current standard-of-care VIA/VILI (292 ver-
sus 239 per 1,000 women screened for HC2 [�20 RLU] and VIA/VILI, respectively), with a
2-fold increase in sensitivity for CIN2+ (96.9% versus 56.3%; RSen = 1.72, 95% CI 1.28–2.32;
S3 Table) but only marginally greater sensitivity for CIN3+ (RSen = 1.18, 95% CI 0.94–1.49).
In SA, HC2 (�1 RLU) had similar sensitivity for CIN3+ as HSIL+ (83.0%, 95% CI 70.2%–
91.9%; RSen = 1.02, 95% CI 0.89–1.18) but lower specificity (42.7%, 95% CI 38.4%–47.1%;
RSpec = 0.57, 95% CI 0.52–0.63), resulting in almost twice as many referrals (597 per 1,000
women) and lower PPV compared to HSIL+ (12.9%, 95% CI 9.5%–16.9%). Increasing the
Fig 2. Sensitivity and specificity of screening strategies for prevalent CIN2+ and CIN3+ in Burkina Faso. (A) CIN2
+; (B) CIN3+. ASCUS+, atypical squamous cells of undetermined significance, or greater; CIN, cervical intraepithelial
neoplasia; HCII, Hybrid Capture 2; HR, high risk; RLU, relative light unit; VIA, visual inspection using acetic acid;
VILI, visual inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.g002
Fig 3. Sensitivity and specificity of screening strategies for prevalent CIN2+ and CIN3+ in South Africa. (A) CIN2
+; (B) CIN3+. CIN, cervical intraepithelial neoplasia; HCII, Hybrid Capture 2; HR, high risk; HSIL+, high-grade
squamous intraepithelial lesion or greater; RLU, relative light unit; VIA, visual inspection using acetic acid; VILI, visual
inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.g003
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threshold to define test positivity decreased the number of referrals in SA but was associated
with a loss in sensitivity (S2 Table).
Using a combination of increased threshold and a restricted genotype approach targeting 8
HR types resulted in the best combination of sensitivity for CIN3+ (countries combined:
77.3%, 95% CI 65.3%–86.7%; Table 3) and specificity for�CIN1 (73.5%, 95% CI 70.6%–
76.2%; Table 2) of any of the HPV-based strategies. Higher sensitivity and specificity for CIN3
+ were observed in BF using this approach (100.0% and 78.2%, respectively; S1 Table).
In both countries, triage of HC2-positive (�1 RLU) women using VIA or VIA/VILI had
similarly low sensitivity for CIN2+ as using VIA or VIA/VILI as a screen test. In BF, although
triage of HC2-positive (�20 RLU) women with VIA/VILI had low sensitivity for CIN2+
(58.1%, 95% CI 39.1%–75.5%; S3 Table), this approach had high sensitivity for CIN3+ (84.6%,
95% CI 54.6%–98.1%; S1 Table) and decreased the number of colposcopy referrals to 100 per
1,000 women. In SA, triage of HC2-positive (�1 RLU) women with cytology HSIL+ increased
the number of referrals compared to HSIL+ alone, from 301 to 363 per 1,000 women, but
referral rate was 40% lower than using HC2 alone (597 per 1,000 women). Although sensitivity
for CIN3+ was high (88.4%, 95% CI 74.9%–96.1%; S2 Table; S4 Table), this approach would
miss 26.9% (14/52) of all women with CIN3+ in SA due to the lower sensitivity of HC2 as a
screen test in SA compared to BF. Triage of HC2-positive women with a combination of
HPV16/18 and HSIL+ had higher sensitivity (95.3%, 95% CI 84.2%–99.4%), with a marginally
higher number of colposcopy referrals (370 per 1,000 women; S2 Table).
Diagnostic accuracy of screening strategies by age at screening
The specificity of HPV tests for�CIN1 increased with increasing age (43.5%, 51.6%, 62.0%,
60.2%, and 63.0% in women aged 25–29, 30–34, 35–39, 40–44, and 45–50 years, respectively;
S5 Table). The PPV increased and test positivity decreased with increasing age, corresponding
with lower HR-HPV prevalence in older age groups. HC2 test positivity was highest and speci-
ficity was lowest in women aged 25–29 years. Triage of women aged 25–29 years using
HPV16/18 with reflex cytology HSIL+ of non-HPV16/18 types generated a sensitivity in triage
for CIN3+ of 100.0% (95% CI 73.5%–100.0%) and specificity of 60.5% (95% CI 51.1%–69.3%),
and triage HPV16/18 with reflex VIA generated a sensitivity and specificity of 91.7% (95% CI
61.5%–99.8%) and 50.0% (95% CI 40.7%–59.3%), respectively (sites combined).
The role of HIV-related factors in diagnostic accuracy of screening
strategies
In both countries, HR-HPV prevalence was higher among ART-naïve women (58.8%) and
recent ART users (�2 years’ duration: 60.6%) compared to prolonged ART users (>2 years:
40.0%; p< 0.001), as was CIN3+ prevalence (5.6%, 8.5%, and 4.5%, respectively, p = 0.064).
The sensitivity of VIA for CIN3+ was lower in women on ART >2 years (42.1%, 95% CI
20.3%–66.5%) compared to women on ART�2 years (64.3%, 95% CI 44.1%–81.4%) or ART-
naïve (55.6%, 95% CI 30.8%–78.5%; S6 Table).
Specificity of HC2 (�1 RLU) for�CIN1 was higher in women on ART >2 years (65.4%,
95% CI 60.3%–70.1%) compared to women on ART�2 years (47.6%, 95% CI 41.4%–53.7%)
or ART-naïve women (46.2%, 95% CI 40.1%–52.4%), corresponding with lower HR-HPV
prevalence in prolonged ART users (S7 Table). Consequently, a higher number of colposcopy
referrals was observed among women on ART�2 years and ART-naïve women. In BF, VIA/
VILI triage of HC2-positive women who were ART naïve or recent ART users decreased the
number of colposcopy referrals from 498 (HC2 alone) to 154 (HC2 followed by VIA/VILI) per
1,000 women, with a good combination of sensitivity and specificity for CIN3+ (85.7%, 95%
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CI 42.1%–99.6%, and 71.9%, 95% CI 63.5%–79.2%). In SA among women taking ART, HSIL
+ was the best performing test for CIN2+ and CIN3+, irrespective of duration of use. Among
ART-naïve women, however, the sensitivity of HSIL+ was low (CIN2+: 53.1%, 95% CI 38.3%–
67.5%; CIN3+: 66.7%, 95% CI 41.0%–86.7%).
HR-HPV type-specific persistence and CIN status over 16 months
Of the 1,130 women evaluated at baseline, 1,042 (92.4%) were seen at the endline visit, at a
median follow-up of 16.2 months (IQR 15.6–16.8), of whom 933 (89.5%) had histology data
available at both time points (BF: 457; SA: 476; Fig 1). The cumulative prevalence of CIN2
+ was 1.3% (6/457) in BF and 9.9% (47/476) in SA (p< 0.001; Table 1), and of CIN3+ was
0.2% (1/457) in BF and 2.7% (13/476) in SA (p< 0.001). There were no invasive cancer cases
detected in either country at endline. Among 809 participants without CIN2+ at baseline, the
incidence of CIN2+ over 16 months was 3.3% (95% CI 2.3%–4.8%) overall and was higher in
SA (BF: 1.2% [5/430]; SA: 5.8% [22/379]; p< 0.001).
At endline, 27 (84.4%) women in BF with CIN2+ detected at baseline who underwent man-
agement of their CIN2/3 lesions returned for the endline visit. In SA, 97 women with CIN2
+ detected at baseline returned for the endline visit, and of these, 61 (63%) underwent manage-
ment before the colposcopy/biopsy endline visit. Of the 36 participants who did not undergo
treatment, 20 (55.6%) had CIN2/3 detected again at endline, and 16 (44.4%) had lower grade
lesions (�CIN1). Of the women who underwent management, the median time from colpos-
copy visit to management was similar in both countries (BF: 10.5 months, IQR 7.3–12.6; SA:
10.7 months, IQR 6.2–13.8).
There were 903 women with matched histology and genotyping at both time points. Type-
specific HR-HPV persistence was 20.7% (156/752) among women who were�CIN1 at both
time points and 77.8% (21/27) among women with incident CIN2+. Among 87 women who
received management for prevalent CIN2+, HR-HPV persistence was 37.0% (30/82) in those
who remained�CIN1 and 66.7% (4/6) in women with CIN2+ redetected at endline (S8
Table). Among 36 women who did not receive management for prevalent CIN2+, HR-HPV
persistence was 70.0% (14/20) in women who remained CIN2+ and 35.3% (6/16) in women
who were�CIN1 at endline (p-trend< 0.001). A test targeting HR-HPV type-specific persis-
tence could detect 73.6% (95% CI 59.7%–84.7%; 39/53) cumulative CIN2+ cases at endline
with a PPV of 16.9% (95% CI 12.3%–22.3%). The proportion of women without CIN2+ at end-
line and with HR-HPV type persistence was 22.6% (95% CI 19.8%–25.5%; 192/880).
CIN2+ incidence at endline among screen-negative women at endline
CIN2+ incidence at endline was 0.5% (95% CI 0.1–1.8) among women with a baseline negative
HC2 (�1 RLU) test or <LSIL on cytology, and 2.2% (95% CI 1.3%–3.7%) among women who
were baseline VIA negative (Table 4). Among HC2-positive women with a triage test (VIA
and HSIL+), incident CIN2+ was higher in the screen/triage-negative women (HC2 followed
by VIA: 2.1%; HC2 followed by HSIL+: 1.8%) compared to women who were negative using
HC2 alone, because of the lower sensitivity of VIA and HSIL+, compared to HC2, for CIN2+.
Discussion
We evaluated the diagnostic accuracy of screen and screen–triage approaches for CIN2
+/CIN3+ in a large prospective cohort of WLHIV from 2 African countries with different HIV
epidemics, different burdens of HPV infection and cervical cancer, and differing approaches
to screening for cervical cancer. This allows the findings to be extended to a range of low- and
middle-income settings. We found that an HPV-DNA-based test had high sensitivity but low
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specificity for CIN2+/CIN3+, but with simple modifications to increase the threshold for test
positivity and with a restricted genotype approach resulted in higher specificity and corre-
spondingly fewer referrals to colposcopy. Triage of HPV-positive women with VIA/VILI in BF
and cytology (HSIL+) in SA resulted in a further reduction in referrals, with minimal impact
on sensitivity for CIN3+, but not for CIN2+.
HPV-based tests have high sensitivity for CIN2+/CIN3+ in both HIV-negative women and
WLHIV, but specificity to distinguish CIN2+ is lower in WLHIV compared to HIV-negative
women [30–34]. HPV-based tests targeting up to 14 HR types, including HC2, careHPV, and
GeneXpert, have all shown high sensitivity but low specificity for CIN2+/CIN3+ in WLHIV
[4–6,31,35,36], due to the high prevalence of HPV infection among these women. In a meta-
analysis of 20 studies evaluating the association between HR-HPV prevalence and the specific-
ity of HPV DNA testing (HC2) to distinguish CIN2+, HC2 specificity decreased by 8.4% (95%
CI 8.02%–8.81%) for each 10% increase in HR-HPV prevalence [7]. In the HARP study,
approximately half of the WLHIV with HR-HPV were infected with 2 or more HR types, and
19% were infected with 3 or more at baseline. Over 16 months, 35% of infections persisted,
and 54% of women acquired a new HR infection [27]. An HPV test that can distinguish clini-
cally relevant from transient HR-HPV infection is thus warranted. Improved specificity could
be achieved with a modified approach to use of HPV DNA by increasing the threshold for test
positivity, corresponding to higher HPV viral load, which is associated with persistent infec-
tion or infection further along the pathway to CIN2+ [26], and by utilising a restricted geno-
type approach to target a smaller number of genotypes that are most associated with cervical
cancer [37]. We have shown in this study that increasing the threshold for test positivity and
restricting the test to specific HR genotypes can increase the specificity of HC2 to distinguish
CIN2+ by 20%. These findings are consistent with a cross-sectional study evaluating the diag-
nostic accuracy of GeneXpert among WLHIV in Cape Town, SA, that reported an increase in
Table 4. CIN2+ incidence at endline among baseline screen-negative women (countries combined).
Strategy N tested Incident CIN2+
screen negative,
n (%, 95% CI)
Incident CIN2+
screen positive,
n (%, 95% CI)
VIA 809 14 (2.2, 1.3–3.7) 13 (7.6, 4.4–12.6)
VIA/VILI 809 11 (1.9, 1.1–3.4) 16 (7.0, 4.3–11.1)
LSIL+ 779 2 (0.5, 0.1–2.1) 25 (6.3, 4.3–9.2)
HSIL+ 779 12 (1.7, 0.9–3.0) 15 (19.0, 11.7–29.3)
HC2 (�1 RLU) 803 2 (0.5, 0.1–1.8) 25 (6.9, 4.7–10.1)
HC2 (�20 RLU) 803 10 (1.7, 0.5–3.2) 17 (7.5, 4.7–11.8)
8 HR types1 788 3 (0.6, 0.2–1.8) 24 (8.5, 5.8–12.4)
HC2 (�1 RLU)! VIA2 807 15 (2.1, 1.3–3.5) 12 (13.0, 7.5–21.7)
HC2 (�20 RLU)! VIA2 803 19 (2.6, 1.6–4.0) 8 (12.3, 6.2–23.0)
HC2 (�1 RLU)! HSIL+2 787 13 (1.8, 1.0–3.1) 14 (21.5, 13.1–33.4)
HC2 (�20 RLU)!HSIL+2 787 17 (2.3, 1.4–3.7) 10 (18.2, 9.9–30.9)
1Positive for HC2 (using a threshold of�1 RLU) and any HPV16/18/31/33/35/45/52/58.
2Incident CIN2+ in baseline screen-negative women calculated among women who were negative for either the
screen or triage test at baseline (i.e., not restricted to screen-positive women to account for women with false-
negative results in the initial screen test); incident CIN2+ in screen-positive women calculated among women who
tested positive for both the screen and triage test.
CIN, cervical intraepithelial neoplasia; HC2, Hybrid Capture 2; HPV, human papillomavirus; HR, high risk; HSIL+,
high-grade squamous intraepithelial lesion or greater; RLU, relative light unit; VIA, visual inspection using acetic
acid; VILI, visual inspection using Lugol’s iodine.
https://doi.org/10.1371/journal.pmed.1003528.t004
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specificity to distinguish CIN2+ from 60% using the manufacturer-defined threshold and tar-
geting 14 HR-HPV types to 77% using a higher threshold to determine test positivity and
restricting analysis to 8 HR-HPV types [31]. There is however some loss in sensitivity associ-
ated with this approach, and a balance will need to be achieved based on capacity to refer
HR-HPV-positive women for colposcopy and treatment.
We also found that the specificity of HC2 varied according to ART status, with the highest
specificity observed in women taking ART for more than 2 years, corresponding with lower
HR-HPV and CIN2+ prevalence. These findings are consistent with that reported in a cohort
of WLHIV undergoing screening in Nairobi, Kenya [5], and Johannesburg, SA [4]. In the
future, all women newly diagnosed with HIV should start ART immediately [38], irrespective
of CD4+ cell count. It is expected that women starting ART at the time of HIV diagnosis who
experience a shorter duration of immunosuppression, or none, will have lower risk of
HR-HPV persistence, CIN2/3 incidence, and cervical cancer compared to WLHIV who may
have initiated ART according to older guidelines [10]. As a consequence, the specificity of
HPV-DNA-based approaches may be higher in these women due to the lower prevalence of
transient or non-clinically relevant HPV infections. An HPV-based strategy using a modified
threshold, with or without a restricted genotype approach, could be a highly accurate and
reproducible screening strategy in these women. However, there will remain a significant pro-
portion of WLHIV who started ART under older guidelines and at lower CD4+ cell count, or
women in settings where early access to ART may be a challenge, who remain at elevated risk.
HPV-based test specificity remained low in these women in our study, irrespective of the
threshold for test positivity or use of a restricted genotype approach. In the short term, it may
be necessary to consider a risk stratification approach with alternative screening strategies for
women with poorly controlled HIV, and if HPV-based tests are used for screening, this group
may require a second test in triage or repeat testing over time due to the low specificity of a
one-time HPV test among these women.
Alternative approaches to the use of HPV tests could include repeat HPV DNA testing over
time, which may distinguish HR-HPV persistent infection associated with CIN2+ from tran-
sient infections. We found in this study that 74% of WLHIV with CIN2+ detected at endline
had type-specific persistence from baseline, compared with 23% of women without CIN2+ at
endline. While such an approach may result in fewer women being unnecessarily treated or
referred to colposcopy, the limitation is the potential for loss to follow-up of screen-positive
women compared to a one-time HPV DNA test. On the other hand, repeat testing over a
shorter interval (e.g., 6 months) may be a feasible approach to integrate in routine HIV care,
where WLHIV may be more frequently followed. Further data collection on the effectiveness
and feasibility of such an approach is warranted.
VIA is commonly used in LMICs, but we have shown it has low sensitivity for CIN2 lesions
in WLHIV, consistent with other studies in Africa [4,5,36], but has higher sensitivity for CIN3
+ in BF only. We also evaluated the diagnostic accuracy of VIA/VILI in HR-HPV-positive
women, but this approach resulted in similarly low sensitivity as for VIA alone, although the
addition of VILI to VIA (i.e., either test positive) improved sensitivity by approximately 15%
for CIN2+/CIN3+. The combination of VIA/VILI also had better accuracy for CIN3+ com-
pared to CIN2+ in BF, but not in SA. This may be because VIA/VILI is more frequently used
as a screening test in BF compared to SA, although study nurses and midwives were trained on
VIA/VILI procedures in a similar way in both settings prior to participant recruitment in this
study. The difference might also be explained by the higher prevalence of other STIs and cervi-
cal inflammation among women in SA compared to women in BF [17], which could impact
the visualisation of the cervix. Visual inspection methods are highly variable due to their sub-
jective nature, and optimal performance is dependent on observer training and experience and
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the availability of quality assurance, including review of digital cervicography to ensure stan-
dardisation of VIA/VILI [4,6,36,39,40], which may be challenging to implement at scale [41].
Computer-aided approaches using automated visual evaluation (AVE) could improve the
accuracy and reproducibility of visual inspection methods. AVE applied to cervigrams has
been evaluated in HIV-negative women in Costa Rica and shown to have higher accuracy
(area under the curve [AUC] = 0.91, 95% CI 0.89–0.93) compared to conventional cytology
(AUC = 0.71, 95% CI 0.65–0.77) [42] but has not yet been studied in WLHIV, although studies
are ongoing.
Cytology was the strategy with the best combination of sensitivity and specificity in SA, but
only when the threshold for test positivity was increased to HSIL+. Similar high accuracy of
cytology for CIN2+/CIN3+ has been reported in other studies in SA, which has an established
cytology-based screening programme with quality control measures routinely implemented
[4]. Studies conducted in the sub-Saharan African region have reported variable sensitivity
and specificity of cytology for CIN2+/CIN3+ in WLHIV [5,40,43–45]; however, in countries
where established cytology services exist, strengthening cytology services should ensure high
accuracy. Sensitivity of HC2 for CIN2+/CIN3+ was higher than that achieved by cytology
HSIL+ in SA, but HC2 detected fewer CIN2+ and CIN3+ cases in SA compared to BF, and the
reasons behind this finding are unclear. Based on genotyping using INNO-LiPA, 11% (8/76)
of women with prevalent CIN2 and 8% (4/53) of women with CIN3 were HR-HPV negative;
5% of CIN2+ cases were negative for any HPV DNA. It is not uncommon to find women with
CIN2+ being HR-HPV negative. A systematic review comparing the HPV type distribution in
ICC biopsy and cervical cell specimens of 770 WLHIV from 21 studies in 12 African countries
reported that prevalence of any HPV was 89% in biopsy samples and 95% in cervical samples
[37]. Similarly, in a review of 10,575 biopsies of ICC, 85% were positive for any HPV [46], and
in a sub-analysis of a large cervical cancer screening study (ATHENA), among 497 cases of
CIN2+, 55 (11%) tested negative by Cobas HPV test and 12 (2.4%) were negative by all HPV
tests (Cobas, Amplicor, and Linear Array) [47]. Our finding of 5% of CIN2+ cases being nega-
tive for any HPV is not dissimilar to the findings of these large international studies. It is
unlikely that CIN2+ cases were misclassified, as all CIN2+ cases were verified by consensus
among 5 independent pathologists [24], although the risk of misclassification cannot be
eliminated.
This study has several limitations. The study maximised the chances of obtaining histologi-
cal results by basing the biopsy decision on positivity of any of 3 screening tests (HC2, cytology
ASCUS+, or VIA/VILI abnormal) or colposcopy (abnormal), to which all participants were
subjected (96% of women underwent all tests). This approach and the threshold to trigger
biopsy for histology are in excess of usual recommendations to minimise ascertainment bias.
The number of post-biopsy adverse events was low; 6 (1.0%) women in BF and 4 (0.6%) in SA
reported post-biopsy bleeding and/or abdominal pain. Women negative by all tests were con-
sidered to be at extremely low risk of CIN2+ since in particular HPV DNA and cytology have
very high NPV for CIN2 diagnosis [48], and it is therefore unlikely that many cases would
have been missed. In addition, the study built a strong review of histological results by consen-
sus of 5 pathologists, which included all histological slides from women with a local diagnosis
of CIN2+ and approximately 10% of slides from women with�CIN1, which showed high
agreement [24]. WLHIV included in this study were recruited from 2011 to 2012, at a time
when they may have started ART according to older guidelines. As such, the study population
may not be representative of contemporary or future cohorts of WLHIV in the universal ART
era. However, our analysis of diagnostic accuracy according to ART status and duration
attempted to correct for this period effect by restricting analysis to women with controlled
HIV, which corresponds to the approach recently used in a contemporary cohort of WLHIV
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enrolled in 2013–2015 in the US [49]. We did not evaluate the HPV tests in the local study set-
tings at baseline, and HC2 was conducted in France due to challenges in acquiring the car-
eHPV assay in time for study initiation. However, careHPV testing was conducted locally at
study sites at endline and showed equivalent diagnostic accuracy as HC2 in a head-to-head
comparison, previously published [21].
Conclusion
HPV-based tests may be sufficient as a screening strategy in WLHIV if a restricted genotype
approach is utilised and a higher threshold for test positivity is established. Molecular-based
tests such as HPV tests have the added advantage of being automatable and less prone to train-
ing and interpretational errors than morphological tests such as VIA/VILI and cytology and
can be performed using the same clinician-collected or self-collected sample, thereby simplify-
ing sample collection, which may facilitate cervical cancer screening without the need for
women to attend clinical services. Cytology remains optimal in settings with an existing cytol-
ogy-based programme, such as SA. ART users with low or unknown nadir CD4+ cell count
and ART-naïve women should be screened frequently, although the optimal screening inter-
vals remain unclear. Although cervical cancer screening is not widely implemented in LMICs,
integration of cervical cancer screening within HIV treatment services would ensure that
women at high risk of developing cervical cancer precursor lesions are screened, and would
lead to continuity in primary prevention, favouring early detection and management of HPV-
related cervical lesions with minimal loss to follow-up [50]. More longitudinal data are needed
on the effectiveness and cost-effectiveness of different cervical cancer screening strategies in
cervical cancer reduction in WLHIV.
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